Estrogen receptor β expression in nevi during pregnancy

Experimental Dermatology

Volumn 17, Issue 6, 2008, Pages 489-497

  Nading, Mary Alice ^a   Nanney, Lillian B ^a   Boyd, Alan S ^a   Ellis, Darrel L ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Veterans Administration   (United States)

Author keywords

Estogen receptor ; Immunohistochemistry; Nevinevocytes; Pregnancy

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ADULT; AGE; ARTICLE; CELL NUCLEUS; CELL POPULATION; CONGENITAL NEVUS; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOPLASM; DERMIS; DYSPLASTIC NEVUS; EPIDERMIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MELANOCYTE; NEVUS CELL; PREGNANCY; PROTEIN EXPRESSION;

ADULT; CELL NUCLEUS; CYTOPLASM; DERMIS; DYSPLASTIC NEVUS SYNDROME; EPIDERMIS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEVUS, PIGMENTED; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; SINGLE-BLIND METHOD; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 43449088554     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00667.x     Document Type: Article

References (41)

1. Elling S V, Powell F C. Physiological changes in the skin during pregnancy. Clin Dermatol 1997: 15: 35-43.
2. Kroumpouzos G, Cohen L M. Dermatoses of pregnancy. J Am Acad Dermatol 2001: 45: 1-19; quiz 19-22.
3. MacKelfresh J, Chen S C, Monthrope Y M. Pregnancy and changes in melanocytic nevi. Obstet Gynecol 2005: 106: 857-860.
4. Sanchez J L, Figueroa L D, Rodriguez E. Behavior of melanocytic nevi during pregnancy. Am J Dermatopathol 1984: 6 (Suppl.): 89-91.
5. Zampino M R, Corazza M, Costantino D, Mollica G, Virgili A. Are melanocytic nevi influenced by pregnancy? A dermoscopic evaluation. Dermatol Surg 2006: 32: 1497-1504.
6. Grin C M, Rojas A I, Grant-Kels J M. Does pregnancy alter melanocytic nevi? J Cutan Pathol 2001: 28: 389-392.
7. Driscoll M S, Grant-Kels J M. Nevi and melanoma in pregnancy. Dermatol Clin 2006: 24: 199-204, vi.
8. Foucar E, Bentley T J, Laube D W, Rosai J. A histopathologic evaluation of nevocellular nevi in pregnancy. Arch Dermatol 1985: 121: 350-354.
9. Ellis D L. Pregnancy and sex steroid hormone effects on nevi of patients with the dysplastic nevus syndrome. J Am Acad Dermatol 1991: 25: 467-482.
10. Pennoyer J W, Grin C M, Driscoll M S et al. Changes in size of melanocytic nevi during pregnancy. J Am Acad Dermatol 1997: 36: 378-382.
11. Rubegni P, Burroni M, Cevenini G et al. Digital dermoscopy analysis and artificial neural network for the differentiation of clinically atypical pigmented skin lesions: A retrospective study. J Invest Dermatol 2002: 119: 471-474.
12. Gunduz K, Koltan S, Sahin M T, Filiz E E. Analysis of melanocytic naevi by dermoscopy during pregnancy. J Eur Acad Dermatol Venereol 2003: 17: 349-351.
13. Rubegni P, Sbano P, Burroni M et al. Melanocytic skin lesions and pregnancy: Digital dermoscopy analysis. Skin Res Technol 2007: 13: 143-147.
14. Pack G T, Scharnagel I M. The prognosis for malignant melanoma in the pregnant woman. Cancer 1951: 4: 324-334.
15. Daryanani D, Plukker J T, De Hullu J A, Kuiper H, Nap R E, Hoekstra H J. Pregnancy and early-stage melanoma. Cancer 2003: 97: 2248-2253.
16. Wiggins C L, Berwick M, Bishop J A. Malignant melanoma in pregnancy. Obstet Gynecol Clin North Am 2005: 32: 559-568.
17. O'Meara A T, Cress R, Xing G, Danielsen B, Smith L H. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005: 103: 1217-1226.
18. Lens M B, Rosdahl I, Ahlbom A et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol 2004: 22: 4369-4375.
19. MacKie R M. Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. Curr Opin Oncol 1999: 11: 129-131.
20. Travers R L, Sober A J, Berwick M, Mihm M C Jr, Barnhill R L, Duncan L M. Increased thickness of pregnancy-associated melanoma. Br J Dermatol 1995: 132: 876-883.
21. Lea C S, Holly E A, Hartge P et al. Reproductive risk factors for cutaneous melanoma in women: A case-control study. Am J Epidemiol 2007: 165: 505-513.
22. McInerney E M, Weis K E, Sun J, Mosselman S, Katzenellenbogen B S. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998: 139: 4513-4522.
23. Mosselman S, Polman J, Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996: 392: 49-53.
24. Pettersson K, Delaunay F, Gustafsson J A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000: 19: 4970-4978.
25. Schmidt A N, Nanney L B, Boyd A S, King L E Jr, Ellis D L. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol 2006: 15: 971-980.
26. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000: 21: 457-487.
27. Schwartz J L, Mozurkewich E L, Johnson T M. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer 2003: 97: 2130-2133.
28. Saenz-Badillos J, Brady M S. Pregnancy-associated melanoma occurring in two generations. J Surg Oncol 2000: 73: 231-233.
29. Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics 1999: 104: 1042-1045.
30. Krengel S. Nevogenesis-new thoughts regarding a classical problem. Am J Dermatopathol 2005: 27: 456-465.
31. Krengel S, Groteluschen F, Bartsch S, Tronnier M. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. J Cutan Pathol 2004: 31: 1-7.
32. Carlson J A, Ross J S, Slominski A et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 2005: 52: 743-775; quiz 775-748.
33. Hsu M Y, Meier F, Herlyn M. Melanoma development and progression: A conspiracy between tumor and host. Differentiation 2002: 70: 522-536.
34. Koehler K F, Helguero L A, Haldosen L A, Warner M, Gustafsson J A. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 2005: 26: 465-478.
35. Slominski A, Wortsman J, Tuckey R C, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol 2007: 266: 143-149.
36. Slominski A, Zjawiony J, Wortsman J et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem 2004: 271: 4178-4188.
37. Scoggins C R, Ross M I, Reintgen D S et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006: 243: 693-698; discussion 698-700.
38. Balch C M, Soong S J, Gershenwald J E et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001: 19: 3622-3634.
39. Buettner P G, Leiter U, Eigentler T K et al. Development of prognostic factors and survival in cutaneous melanoma over 25years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005: 103: 616-624.
40. Goldberg M S, Doucette J T, Lim H W, Spencer J, Carucci J A, Rigel D S. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-2005. J Am Acad Dermatol 2007: 57: 60-66.
41. Richardson B, Price A, Wagner M et al. Investigation of female survival benefit in metastatic melanoma. Br J Cancer 1999: 80: 2025-2033.